Хумалог: досвід клінічного застосування у дітей і підлітків із цукровим діабетом 1-го типу

О. В. Большова, О. Я. Самсон

Анотація


The authors present the results of the use of an insulin analogue rapid-acting Humalog (lispro), in children and adolescents with type 1 diabetes mellitus. Humalog was found to be an effective, safe, and comfortable for the basal-bolus regimes of insulin therapy, that contributes to postprandial glycemic control. Humalog reduces glycolysated hemoglobin level, associates with decreasing of hypoglycemia incidence, especially at night, and improves patients' quality of life.

Ключові слова


children and adolescents; type 1 diabetes mellitus; rapid- acting insulin analogues; Humalog (lispro)

Повний текст:

PDF

Посилання


Nathan D.M., Zinman B., Cleary P.A., Backlund J.Y., Genuth S., Miller R., Orchard T.J. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) // Arch. Intern. Med. – 2009. – Vol.169(14). – P. 1307-1316. https://doi.org/10.1001/archinternmed.2009.193

Ford-Adams M.E., Murphy N.P., Moore E.J., Edge J.A., Ong K.L., Watts A.P., Acerini C.L., Dunger D.B. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus // Diabet. Med. – 2003. – Vol.20(8). – P. 656-660. https://doi.org/10.1046/j.1464-5491.2003.01013.x

Slieker L.J. et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor // Diabetologia. – 1997. – Vol.40(14). – P. S54-S61. https://doi.org/10.1007/s001250051402

Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin // Diabetes. – 1994. – Vol.43. – P. 396-402. https://doi.org/10.2337/diabetes.43.3.396

Ebeling P., Jansson P.A., Smith U., Lalli C., Bolli G.B., Koivisto V.A. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin // Diabetes Care. – 1997. – Vol.20. – P. 1287-1289. https://doi.org/10.2337/diacare.20.8.1287

Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., Anderson J.H. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group // Diabetes Care. – 1997. – Vol.20(12). – P. 1827-1832. https://doi.org/10.2337/diacare.20.12.1827

Chase H.P., Lockspeiser T., Peery B., Shepherd M., MacKenzie T., Anderson J., Garg S.K. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes // Diabetes Care. – 2001. – Vol.24(3). – P. 430-434. https://doi.org/10.2337/diacare.24.3.430

Peczynska J., Urban M., Glowinska B., Florys B. Decreased consciousness of hypoglycaemia and the incidence of severe hypoglycaemia in children and adolescents with diabetes type 1 // Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw. – 2002. – Vol.8(2). – P. 77-82.

Berhe T., Postellon D., Wilson B., Stone R. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study // Pediatrics. – 2006. – Vol.117(6). – P. 2132-2137. https://doi.org/10.1542/peds.2005-2363

Brunelle B.L., Llewelyn J., Anderson J.H.Jr., Gale E.A., Koivisto V.A. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes // Diabetes Care. – 1998. – Vol.21(10). – P. 1726-1731. https://doi.org/10.2337/diacare.21.10.1726

Fineberg S.E., Huang J., Brunelle R., Gulliya K.S., Anderson J.H.Jr. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes // Diabetes Care. – 2003 – Vol.26(1). – P. 89-96. https://doi.org/10.2337/diacare.26.1.89

Danne T., Deiss D., Hopfenmuller W., von Schutz W., Kordonouri O. Experience with insulin analogues in children // Horm. Res. – 2004. – Vol.57(1). – P. 46-53. https://doi.org/10.1159/000053312

Garg S., Ampudia-Blasco F.J., Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus // Endocr. Pract. – 2010. – Vol.16(3). – P. 486-505. https://doi.org/10.4158/ep09294.ra

Miles H.L., Acerini C.L. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus // Paediatr. Drugs. – 2008. – Vol.10(3). – P. 163-176. https://doi.org/10.2165/00148581-200810030-00005

Singh S.R., Ahmad F., Lal A., Yu C., Bai Z., Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a metaanalysis // CMAJ. – 2009. – Vol.180(4). – P. 385-397. https://doi.org/10.1503/cmaj.081041


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.24026/1818-1384.4(37).2011.86634

Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія.

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter